Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Many statements about what constitutes “high dose,” dose thresholds (e.g., ≥1 g per dose or “multi-gram per day”), and dose-dependent risk are not supported by the provided FDA label excerpts, which do not define a universal or categorical “high-dose” term or provide dose-threshold language for common adverse reactions. Some safety concepts (e.g., acute renal failure, CNS effects, need for renal dose reduction) are broadly consistent with labeled cautions, but several claims go beyond the label’s wording.
Category Scores
Accurate Statements
Clinicians may lower the valacyclovir dose or adjust the dosing interval for safety in people with kidney impairment.
Supported indirectly: The label states “Dosage reduction is recommended when administering VALTREX to patients with renal impairment [see Dosage and Administration (2.4), Warnings and Precautions (5.2, 5.3)].” It also states acute renal failure occurred in patients with underlying renal disease who received higher-than-recommended doses, and that dosage reduction is recommended for renal impairment.
The risk of dose-related side effects is especially increased in people with reduced kidney function.
Partially supported: Label warns about acute renal failure (5.2) and CNS effects (5.3) with patients with or without reduced renal function and notes elderly patients are more likely to have CNS adverse reactions; and it reports events with “higher-than-recommended doses … for their level of renal function.” However, the label excerpts provided do not explicitly frame this as a generalized “dose-related side effects” risk increase specifically in reduced kidney function.
Unsupported Statements
There is not one universal “high-dose” label for valacyclovir; the definition depends on the reason it is being taken, kidney function, and the specific regimen prescribed.
The provided label excerpts do not define any universal or non-universal “high-dose” term, nor do they provide a framework explaining how a label would define “high dose” by indication/reason and kidney function.
Clinicians and prescribing references treat dosing above the usual everyday ranges as “high.”
The label excerpts do not use or define “high dose” in this way.
Higher total daily amounts are used for serious or time-sensitive herpes infections.
The label excerpts provide specific adult dosing regimens by indication (e.g., cold sores, initial/recurrent genital herpes, suppressive therapy, herpes zoster), but they do not state or justify this as “higher total daily amounts are used for serious or time-sensitive infections.”
Regimens at or above 1,000 mg (1 g) per dose given multiple times per day are considered high-dose valacyclovir.
No label excerpt defines “high-dose” thresholds by mg per dose.
A valacyclovir regimen totaling several grams per day (e.g., 3 g/day or more) is typically viewed as a high-dose regimen.
No label excerpt provides a “several grams/day” or “3 g/day or more” definition tied to “high dose.”
For many suppressive or chronic herpes regimens, the total daily dose is often 500 mg once daily or 1 g once daily.
This is not directly supported by the provided label excerpts as a general statement (“often”). The label excerpts show specific suppressive therapy doses (e.g., 1 g once daily alternative 500 mg once daily; and HIV-1-infected patients 500 mg twice daily), but do not support a generalized “often” across many regimens.
Suppressive or chronic herpes regimens with 500 mg once daily or 1 g once daily would not usually be described as “high.”
The label excerpts do not provide any definition or categorization of “high dose.”
For acute, more intensive treatment such as shingles (herpes zoster) or severe outbreaks, prescriptions commonly involve larger daily totals, often in the multi-gram per day range.
While herpes zoster dosing in the label includes 1 gram 3 times daily (3 g/day), the label excerpts do not support the broader claims about “commonly,” “more intensive,” “severe outbreaks,” or the “multi-gram per day range” as a general meaning of “high dose.”
High daily totals for acute treatment are the regimens most people mean when they ask what “high dose” means.
This is not supported in the label excerpts; the label does not define what people mean by “high dose.”
High-dose valacyclovir regimens raise the risk of dose-related side effects.
The label excerpts support that acute renal failure and CNS adverse reactions have been reported especially in patients with underlying renal disease who received higher-than-recommended doses for their level of renal function. However, the provided excerpts do not support a general statement that “high-dose valacyclovir regimens” raise risk of “dose-related side effects” broadly in the way claimed, nor do they define “high-dose.”
Kidney impairment can cause valacyclovir drug levels to build up.
The provided label excerpts do not state that kidney impairment causes valacyclovir drug levels to build up.
If a person has chronic kidney disease or has renal dose adjustment, what counts as “high dose” may be lower than what would be considered high in someone with normal kidney function.
The label excerpts do state that dosage reduction is recommended in renal impairment and that events occurred in patients who received higher-than-recommended doses for their renal function. But they do not explicitly define “what counts as high dose” as being “lower” for CKD or normal kidney function.
Contradictions
Low
AI Statement
Regimens at or above 1,000 mg (1 g) per dose given multiple times per day are considered high-dose valacyclovir.
Label Reference
No contradiction stated directly; label provides dosing but does not define “high dose.”
Low
AI Statement
A valacyclovir regimen totaling several grams per day (e.g., 3 g/day or more) is typically viewed as a high-dose regimen.
Label Reference
No contradiction stated directly; label provides dosing but does not define “high dose.”
Important Omissions
No label-supported definition or categorization of “high dose” (mg/day or mg/dose thresholds) is provided; the label provides specific recommended regimens by indication and renal impairment tables, but not a “high-dose” label concept.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the label supports caution for higher-than-recommended dosing in renal impairment and warns about acute renal failure and CNS effects, multiple statements introduce an undefined “high-dose” framework and dose-threshold language not supported by the provided label excerpts. This could mislead a reader about what dosing levels are considered “high” versus simply “recommended for an indication” (e.g., herpes zoster is 3 g/day in the label).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims define “high-dose” by mg/day or mg/dose thresholds and generalize risk mechanisms/level build-up without support in the provided label excerpts.
Suggested Improvement
Replace the undefined “high-dose” thresholds and generalizations with label-supported dosing regimens by indication and the label’s explicit cautions: (1) recommended adult dosing amounts, (2) dosage reduction recommended for renal impairment, and (3) warnings about acute renal failure and CNS effects occurring particularly with higher-than-recommended doses for renal function.